Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupPlasma cell neoplasmsTransplantationDiseaseMultiple MyelomaStem Cell mobilizationStem Cell Transplantation, AutologousSubgroupICD10C90.-C90.0-Z94.80MeSHHematopoietic Stem Cell MobilizationMultiple MyelomaPlasmacytomaSequenceIFM 2009/DETERMINATION: BORT1.3/LENA25/DEXA20, Ind., MM (PID1036) -|- cons. after ASCT (PID1040) or cons. without ASCT (PID1037) -|- maint. after ASCT (PID891) or maint. (PID2181)ChemotherapyChemo-substanceBortezomibCyclophosphamideDexamethasoneLenalidomideMelphalanChemo-substanceBortezomibCyclophosphamideDexamethasoneLenalidomideMelphalanChemo-substanceBortezomibCyclophosphamideDexamethasoneLenalidomideMelphalanChemo-substanceBortezomibCyclophosphamideDexamethasoneLenalidomideMelphalanNo. Substances13 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneFilgrastimFosaprepitantFurosemideGranisetronMesnaPantoprazolePlerixaforSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneFilgrastimFosaprepitantFurosemideGranisetronMesnaPantoprazolePlerixaforSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneFilgrastimFosaprepitantFurosemideGranisetronMesnaPantoprazolePlerixaforSupportive substanceAcetylsalicylic acidAciclovirAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDalteparinDexamethasoneFilgrastimFosaprepitantFurosemideGranisetronMesnaPantoprazolePlerixaforNo. Substances568Protocol classificationTherapy classificationalternativecurrent standardstudy analogIntensityhigh doseHigh dose myeloablativeStandard doseTherapy indicationFirst lineTherapy phaseconditioningConsolidationMaintenanceTherapy intentioncurativedisease controlRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaInfectionsNeuropathyNeutropeniaRashThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAttal MGoldschmidt HMcCarthy PRichardson PDiseaseMM Stadium II und III, 18 - 65 Jahre, ECOG 0-3 (3 nur wenn durch Myelom bedingt), ErstlinieMM Stadium II und III, 18-65 Jahre, ECOG 0-3, ErstlinieMultiples Myelom, ECOG 0-1multiples Myelom, Erstdiagnose nach Induktionstherapie und autologer Transplantation, ECOG 0-1neudiagnostiziertes multiples Myelom, < 65 JahreOriginBMT Program, Roswell Park Cancer Institute, Buffalo, NY, CALGB 100104German-Speaking Myeloma Multicenter Group (GMMG), Therapieteil analog der HD-3 StudieHOVON-65/GMMG-HD4 StudieIFm2009 / Determination trialInstitut Universitaire du Cancer de Toulouse-Oncopole and Service d’Epidémiologie, Toulouse, IFM 2009 StudyProtocols in Revision 5 protocols foundProtocols under revision.Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 10, Multiple Myeloma, Consolidation after Autologous Stem Cell Transplantation. (PID1040 V1.2)High dose Cyclophosphamide 2000 for stem cell mobilization, Multiple Myeloma (PID535 V1.0.1)High-dose Melphalan 200 before Autologous Stem Cell Transplantation, Multiple Myeloma (PID528 V2.2)Lenalidomide 10, Multiple Myeloma, maintenance (PID2181 V1.0)Lenalidomide 10, Multiple Myeloma, Maintenance after Autologous Stem Cell Transplantation, Autologous (PID891 V1.1)
